AXSM
AXSM clinical trials: Axsome Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Axsome Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 42
- Trials linked
- 37
- As lead sponsor
- 5
- As collaborator
- 2
- Primary completions as lead sponsor, next 90 days
AXSM on the catalyst calendar · AXSM registry changes
- Primary completion Mar 2028Sponsor estimatePhase 3NCT07398417Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research DesignAxsome Therapeutics, Inc. · FibromyalgiaRecruitingAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 3NCT06878976A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating DisorderAxsome Therapeutics, Inc. · Binge-Eating DisorderEnrolling by invitationAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 3NCT07773883An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHDAxsome Therapeutics, Inc. · ADHDEnrolling by invitationAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 3NCT07766655Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)Axsome Therapeutics, Inc. · Smoking CessationRecruitingAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2028Sponsor estimatePhase 3NCT07717892Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)Axsome Therapeutics, Inc. · ADHDRecruitingAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2028Sponsor estimatePhase 3NCT07717879Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)Axsome Therapeutics, Inc. · ADHDRecruitingAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2028Sponsor estimatePhase 3NCT07637162Open-Label Safety Study of AXS-14 in Subjects With FibromyalgiaAxsome Therapeutics, Inc. · FibromyalgiaEnrolling by invitationAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 3NCT07484217Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using SolriamfetolAxsome Therapeutics, Inc. · Major Depressive Disorder With Excessive Daytime Sleepiness SymptomsRecruitingAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2029Sponsor estimateNo phase registeredNCT06413420SUNOSI® (Solriamfetol) Pregnancy RegistryAxsome Therapeutics, Inc. · NarcolepsyRecruitingAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT06413433Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using SolriamfetolAxsome Therapeutics, Inc. · Binge-Eating DisorderRecruitingAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT06568367Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)Axsome Therapeutics, Inc. · Excessive SleepinessRecruitingAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 21, 2024ActualPhase 3NCT05557409A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease AgitationAxsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's TypeCompletedAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 17, 2025ActualPhase 3NCT06736509An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2...Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's TypeTerminatedAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 15, 2024ActualPhase 3NCT05059223A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With NarcolepsyAxsome Therapeutics, Inc. · NarcolepsyCompletedAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2019ActualPhase 2NCT03881852Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)Axsome Therapeutics, Inc. · NarcolepsyCompletedAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 7, 2025ActualPhase 3NCT05972044A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)Axsome Therapeutics, Inc. · ADHDCompletedAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 19, 2022ActualPhase 4NCT04789174Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled StudyAxsome Therapeutics, Inc. · Excessive Daytime SleepinessCompletedAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 18, 2022ActualPhase 2NCT04634669Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)Axsome Therapeutics, Inc. · Treatment Resistant DepressionTerminatedAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 16, 2020ActualPhase 3NCT04163185Initiating Early Control of Migraine Pain and Associated SymptomsAxsome Therapeutics, Inc. · MigraineCompletedAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2024ActualPhase 3NCT06360419Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolAxsome Therapeutics, Inc. · Major Depressive DisorderCompletedAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2024ActualPhase 3NCT04947553A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease AgitationAxsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's TypeCompletedAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2024ActualPhase 3NCT05550207Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)Axsome Therapeutics, Inc. · MigraineCompletedAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2024ActualPhase 3NCT05113745A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)Axsome Therapeutics, Inc. · NarcolepsyCompletedAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2026Sponsor estimatePhase 4NCT06223880A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive SymptomsAxsome Therapeutics, Inc. · Major Depressive DisorderRecruitingAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 21, 2022ActualPhase 3NCT04797715Assessing Clinical Outcomes in Alzheimer's Disease AgitationAxsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's TypeCompletedAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 17 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner